• Patient must be \> or equal to18 years of age and must have provided written informed consent.

• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

• Histologically confirmed Grade 2 NET, Ki-67 of 3-20%, from pancreatic or intestinal origin.

• Patient clinically suitable for PRRT

• Tumor SSR uptake on GaTate PET/CT higher than liver activity, ≥ modified Krenning 3 score

• No discordant FDG-avid disease on FDG PET/CT

• No evidence of significant uncorrected carcinoid heart disease

• Patients must be willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled assessments

• Patients must have adequate bone marrow, hepatic and renal function defined as:

‣ Haemoglobin ≥100 g/L

⁃ Absolute neutrophil count ≥1.5x109/L

⁃ Platelets ≥150 x109/L

⁃ Total bilirubin ≤1.5 x upper limit of normal (ULN)

⁃ Aspartate transaminase (AST) (SGOT) and alanine transaminase (ALT) (SGPT)

‣ ≤2.5 x ULN if there is no evidence of liver metastasis or ≤5 x ULN in the presence of liver metastases.

⁃ Albumin ≥ 30 g/L

⁃ Adequate renal function: eGFR ≥ 50 ml/min